Antiproliferative effects of 111In- or 177Lu-DOTATOC on cells exposed to low multiplicity-of-infection double-deleted vaccinia virus encoding somatostatin subtype-2 receptor

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 3, 2010, Pages 325-333

  Akinlolu, Olayinka ^a   Ottolino Perry, Kathryn ^b   McCart, Judith Andrea ^b,c   Reilly, Raymond M ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

111In DOTATOC; 177Lu DOTATOC; antiproliferative effects; multiplicity of infection (MOI; vaccinia virus

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID PHENYLTYROSINE OCTREOTIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID PHENYLTYROSINE OCTREOTIDE LU 177; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; 111IN DOTA TOC; 111IN-DOTA-TOC; 177LU OCTREOTIDE, DOTA(0) TYR(3); 177LU-OCTREOTIDE, DOTA(0)-TYR(3)-; DRUG DERIVATIVE; OCTREOTIDE; SOMATOSTATIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL VIABILITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOSIMETRY; DOUBLE DELETED VACCINIA VIRUS; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPHEROID CELL; VACCINIA VIRUS; ADENOCARCINOMA; ANIMAL; CELL LINE; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; COLON TUMOR; CYTOPLASM; GENE DELETION; GENETICS; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; ONCOLYTIC VIROTHERAPY; PHYSIOLOGY; RADIATION DOSE; RADIATION EXPOSURE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; CYTOPLASM; GENE DELETION; HUMANS; MICE; NEOPLASMS; OCTREOTIDE; ONCOLYTIC VIROTHERAPY; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TRANSFECTION; VACCINIA VIRUS;

EID: 77954938182     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0713     Document Type: Article

References (27)

1. Van Essen M, Krenning EP, Kam BL, et al. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009;5:382.
2. Kwekkeboom DJ, De Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124.
3. Delpassand ES, Sims-Mourtada J, Saso H, et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm 2008;23:292.
4. Anthony LB, Woltering EA, Espenan GD, et al. Indium-111- pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002;32:123.
5. Hofland LJ, Lamberts SW. Somatostatin receptor subtype expression in human tumors. Ann Oncol 2001;12(suppl2): 531.
6. Reubi JC, Krenning E, Lamberts SW, et al. Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol 1990;37:1073.
7. McCart JA, Mehta N, Scollard D, et al. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: Molecular imaging after systemic delivery using 111In- pentetreotide. Mol Ther 2004;10:553.
8. McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thy- midine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751.
9. Brader P, Kelly KJ, Chen N, et al. Imaging a genetically engineered oncolytic vaccinia virus (GLV-1h99) using a human norepinephrine transporter reporter gene. Clin Cancer Res 2009;15:3791.
10. de Jong M, Breeman WAP, Bernard BF, et al. Tumor response after [90Y-DOTA0,Tyr3]-octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001;42:1841.
11. Boyd M, Ross SC, Dorrens J, et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with a-, b-, and Auger electron-emitting radionuclides. J Nucl Med 2006;47:1007.
12. Baragli A, Alturaihi H, Watt HL, et al. Heterooligomeriza- tion of human dopamine receptor 2 and somatostatin receptor 2 co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 2007;19:2304.
13. Ivascu A, Kubbies M. Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis. J Biomol Screen 2006;11:922.
14. Breeman WAP, de Jong M, Visser TJ, et al. Optimising conditions for radiolabeling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917.
15. Storch D, Behe M, Walter MA, et al. Evaluation of [99mTc/ EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3,Thr8] octreotide and [111In-DTPA0]- octreotide: Does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 2005;46:1561.
16. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: Absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 1994; 35:303.
17. Howell RW, Bouchet LG, Bolch WE, et al. MIRD Cellular S-Values. Reston, VA: The Society of Nuclear Medicine, 1997.
18. Chen P, Wang J, Hope K, et al. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med 2006; 47:827.
19. Costantini DL, Chan C, Cai Z, et al. 111In-labeled trastuzu- mab (Herceptin) modified with nuclear localization sequences (NLS): An Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007;48:1357.
20. 111Inlabeled EGF is selectively radiotoxic to human breast cancer cells over-expressing EGFR. J Nucl Med 2000;41:429.
21. Xue LY, Butler NJ, Makrigiorgos GM, et al. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci U S A 2002;99:13765.
22. Reilly RM. Biomolecules as targeting vehicles for in situ radiotherapy of malignancies. In: Knaeblein J, Mueller R (eds.), Modern Biopharmaceuticals: Design, Development and Optimization. Weinheim, Germany: Wiley-VCH, 2005;497.
23. Ginj M, Hinni K, Tschumi S, et al. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using Auger electron emitters. J Nucl Med 2005;46:2097.
24. Djordjevic B, Lange CS. Cell-cell interactions in spheroids maintained in suspension. Acta Oncol 2006;45:412.
25. Boyd M, Sorensen A, McCluskey AG, et al. Radiation quality-dependent bystander effects elicited by targeted radionuclides. J Pharm Pharmacol 2008;60:951.
26. Worschech A, Haddad D, Stroncek DF, et al. The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother 2009;58:1355.
27. Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or meta-static liver cancer: A phase I trial. Lancet Oncol 2008;9:533.